BMY Bristol Myers Squibb

Q2 2025 10-Q

Filed: Jul 31, 2025Period ending Jun 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Bristol Myers Squibb (BMY) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Jul 31, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Management Discussion & Analysis

• Total expenses $10.5B Q2 2025, down 4% from $10.9B Q2 2024; cost of products sold up 3% to $3.37B Q2 2025 vs $3.27B Q2 2024
• SG&A down 11% to $1.71B Q2 2025 vs $1.93B Q2 2024; R&D decreased 11% to $2.58B from $2.90B Q2 2024

+4 more insights

Risk Factors

• New product approval risk: FDA approved Opdivo + Yervoy for unresectable/metastatic HCC and CRC in April 2025, impacting market launch timing
• Material regulatory update: EC approved Opdivo Qvantig for multiple adult solid tumors May 2025, expanding commercial indications significantly

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$12.3B

▲ +0.6% YoY▲ +9.5% QoQ

Net Income

$1.3B

▼ -22.0% YoY▼ -46.7% QoQ

Net Margin

10.7%

▼ -309bp YoY▼ -1125bp QoQ

Source: XBRL data from Bristol Myers Squibb Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Bristol Myers Squibb Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Bristol Myers Squibb

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.